Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate

Virginia Ferraresi, Caterina Catricalà, Mariangela Ciccarese, Angela Ferrari, Massimo Zeuli, Francesco Cognetti

Research output: Contribution to journalArticlepeer-review

Abstract

Imatinib mesylate is a selective protein kinase inhibitor, highly active in patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Cutaneous toxicity, a well-recognized, dose-related side-effect of imatinib mesylate, has been reported in 18 to 69% of patients with GIST treated with doses ranging from 400 to 800 mg once a day. In this case-report a severe skin reaction observed in a patient with GIST treated with imatinib mesylate, in an adjuvant setting and whose severity led to definitive drug discontinuation, is described. Therapeutic management and clinical course are illustrated.

Original languageEnglish
Pages (from-to)4771-4774
Number of pages4
JournalAnticancer Research
Volume26
Issue number6 C
Publication statusPublished - Nov 2006

Keywords

  • Imatinib mesylate
  • Skin toxicity
  • Supportive care

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate'. Together they form a unique fingerprint.

Cite this